ArticleFrontiers in medicine2025
Predicting liver metastasis in pancreatic neuroendocrine tumors with an interpretable machine learning algorithm: a SEER-based study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development of an interpretable machine learning model for predicting intestinal necrosis in older patients with incarcerated hernia: A retrospective cohort study.The Journal of international medical research · 2026Article
- Predicting the Unpredictable: AI-Driven Prognosis in Pancreatic Neuroendocrine Neoplasms.Cancers · 2026Review
- Developing and Interpreting a Machine Learning Model for Identifying Liver Metastasis in Gastric Cancer.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver metastasis is the most common site of metastasis in pancreatic neuroendocrine tumors (PaNETs), significantly affecting patient prognosis. This study aims to develop machine learning algorithms to predict liver metastasis in PaNETs patients, assisting clinicians in the personalized clinical decision-making for treatment. Methods: We collected data on eligible PaNETs patients from the Surveillance, Epidemiology, and End Results (SEER) database for the period from 2010 to 2021. The Boruta algorithm and the Least Absolute Shrinkage and Selection Operator (LASSO) were used for feature selection. We applied 10 different machine learning algorithms to develop models for predicting the risk of liver metastasis in PaNETs patients. The model's performance was assessed using a variety of metrics, including the area under the receiver operating characteristic curve (AUC), the area under the precision-recall curve (AUPRC), decision curve analysis (DCA), calibration curves, accuracy, sensitivity, specificity, F1 score, and Kappa score. The SHapley Additive exPlanations (SHAP) were employed to interpret models, and the best-performing model was used to develop a web-based calculator. Results: The study included a cohort of 7,463 PaNETs patients, of whom 1,356 (18.2%) were diagnosed with liver metastasis at the time of initial diagnosis. Through the combined use of the Boruta and LASSO methods, T-stage, N-stage, tumor size, grade, surgery, lymphadenectomy, chemotherapy, and bone metastasis were identified as independent risk factors for liver metastasis in PaNETs. Compared to other machine learning algorithms, the gradient boosting machine (GBM) model exhibited superior performance, achieving an AUC of 0.937 (95% CI: 0.931-0.943), an AUPRC of 0.94, and an accuracy of 0.87. DCA and calibration curve analyses demonstrate that the GBM model provides better clinical decision-making capabilities and predictive performance. Furthermore, the SHAP framework revealed that surgery, N-stage, and T-stage are the primary decision factors influencing the machine learning model's predictions. Finally, based on the GBM algorithm, we developed an accessible web-based calculator to predict the risk of liver metastasis in PaNETs. Conclusion: The GBM model excels in predicting the risk of liver metastasis in PaNETs patients, outperforming other machine learning models and providing critical support for developing personalized medical strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.